Comparative Pharmacology
Head-to-head clinical analysis: DESOGESTREL AND ETHINYL ESTRADIOL versus OGEN 1 25.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DESOGESTREL AND ETHINYL ESTRADIOL versus OGEN 1 25.
DESOGESTREL AND ETHINYL ESTRADIOL vs OGEN 1.25
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Desogestrel is a progestin that suppresses gonadotropin release, inhibiting ovulation. Ethinyl estradiol is an estrogen that provides negative feedback on the hypothalamic-pituitary axis, further suppressing ovulation and altering cervical mucus and endometrial lining to reduce sperm penetration and implantation.
Estrogen replacement therapy; binds to estrogen receptors (ERα and ERβ), modulating gene transcription and exerting effects on reproductive tissues, bone density, and cardiovascular system.
One tablet (0.15 mg desogestrel/0.03 mg ethinyl estradiol) orally once daily for 21 days, followed by 7 placebo tablets, then repeat cycle.
1.25 mg orally once daily for 3 weeks, followed by a 1-week rest period; cyclic therapy.
None Documented
None Documented
Desogestrel: terminal half-life 23-27 hours (active metabolite etonogestrel); clinically allows once-daily dosing. Ethinyl estradiol: terminal half-life 12-15 hours (range 10-20 hours) with biphasic elimination; supports daily administration.
Terminal elimination half-life: 10–24 hours (mean ~15 h); clinically, steady-state achieved in 5–7 days
Desogestrel: primarily renal (approximately 60% as metabolites), 30% fecal. Ethinyl estradiol: primarily renal (approximately 40% as glucuronide conjugates), 60% fecal.
Renal: 95% (as glucuronide and sulfate conjugates); biliary/fecal: ~5%
Category D/X
Category C
Estrogen
Estrogen